Bioxodes is a clinical stage biotech company specialized in the development of novel therapeutics using molecules derived from nature to prevent thrombosis and inflammatory processes.
04/29/2021 - Bioxodes announces the
completion of the active phase of its First-in-Human study
performed in healthy adult volunteers with Ir-CPI, a drug candidate for the prevention of thrombosis.
Read the full Press Release
Mission & Vision
Potential therapeutic applications
Copyright Bioxodes |